Cinclus Pharma announces listing on Nasdaq Stockholm and offering of ordinary shares as well as publishes related prospectus
Cinclus Pharma Holding AB (publ) (“Cinclus Pharma” or the “Company”), a Swedish clinical stage pharmaceutical company, has resolved to diversify the shareholder base through an offering of newly issued ordinary shares (the “Offering”) and has at the same time applied for listing of the Company’s ordinary shares on Nasdaq Stockholm (the “Listing”). Nasdaq Stockholm’s Listing Committee has resolved to admit the Company’s ordinary shares to trading, subject to the fulfillment of certain customary conditions no later than on the first day of trading. The prospectus relating to the Offering and the Listing, including the price and other terms of the Offering, is published today and the first day of trading is expected to be 20 June 2024.
Christer Ahlberg, CEO of Cinclus Pharma, comments:
“We are very excited about this important step in Cinclus Pharma’s development. By becoming the product that can offer 24-hour acid control and healing for the most severely ill patients with eGERD, our drug candidate linaprazan glurate has the potential to drive a paradigm shift in the treatment of gastric acid-related diseases. The listing of Cinclus Pharma on Nasdaq Stockholm is a logical and important step that enables continued development of linaprazan glurate. We have received very positive feedback from potential investors, making us feel incredibly excited to take the next step in this process. There is a significant need for a more effective treatment of gastric acid-related diseases, which position Cinclus Pharma well to create value for our shareholders.”
Read the full Press Release behind disclaimer:
Link to related articles:
[Swedish link] Placera: Cinclus Pharma till börsen
Links to related articles on external sites that can be read by subscription:
[Swedish link] Di's information confirmed: Cinclus Pharma goes public
Cinclus Pharma Seeks $117 Million Valuation in Stockholm IPO
[Swedish link] Läkemedels-VD:n om noteringen: ”Vi är ett lågriskprojekt”
[Swedish link] Affärsvärlden: Cinclus Pharma: IPO i rätt fas
Interview with Christer Ahlberg, CEO of Cinclus Pharma, in DiTV:
[Swedish link] Cinclus Pharma till börsen: Räknar med godkänt läkemedel 2029
